Rare essentials: drugs for rare diseases as essential medicines
Since 1977, the WHO Model List of Essential Medicines (EML), published by WHO, has provided advice for Member States that struggle to decide which pharmaceutical technologies should be provided to patients within their public health systems. Originating from outside WHO, an incentive system has been...
Main Authors: | Pieter Stolk, Marjolein JC Willemen, Hubert GM Leufkens |
---|---|
Format: | Article |
Language: | English |
Published: |
The World Health Organization
2006-09-01
|
Series: | Bulletin of the World Health Organization |
Online Access: | http://www.scielosp.org/scielo.php?script=sci_arttext&pid=S0042-96862006000900018&lng=en&tlng=en |
Similar Items
-
Are drugs for rare diseases "essential"?
by: Marcus M Reidenberg
Published: (2006-09-01) -
Are drugs for rare diseases "essential"?
by: Marcus M Reidenberg -
Selection of essential medicines for diabetes in low and middle income countries: a survey of 32 national essential medicines lists.
by: Yaser T Bazargani, et al.
Published: (2014-01-01) -
Drug Repurposing for Rare Diseases: A Role for Academia
by: Sibren van den Berg, et al.
Published: (2021-10-01) -
Essential list of medicinal products for rare diseases: recommendations from the IRDiRC Rare Disease Treatment Access Working Group
by: William A. Gahl, et al.
Published: (2021-07-01)